This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hashimoto, Y. Articles by Tanaka, T. Search for Related Content PubMed PubMed Citation Articles by Hashimoto, Y. Articles by Tanaka, T.

Exogenous 20K Growth Hormone (GH) Suppresses Endogenous 22K GH Secretion in Normal Men

Institute of Biological Science (Y.H., M.H., K.M.), Mitsui Pharmaceuticals, Inc., Chiba 297-0017; Clinical Development Department (T.K., A.M., Y.S.), Mitsui Pharmaceuticals, Inc., Tokyo 103-0027; Komagome-higashi Clinic (M.T.), Kiyaku-kai Medical Corporation Hohsen Clinic, Tokyo 170-0003; and Department of Endocrinology and Metabolism (T.T.), National Children’s Medical Research Center, Tokyo 154-8509, Japan

Address correspondence and requests for reprints to: Yoshihide Hashimoto, Ph.D., Senior Scientist, Institute of Biological Science, Mitsui Pharmaceuticals, Inc., 1900–1 Togo, Mobara, Chiba 297-0017, Japan.

The physiological and pharmacological functions of the 20-kDa human GH (20K-hGH) isoform are unknown. We conducted a pharmacokinetic study of recombinant 20K-hGH in human subjects (Phase I clinical trial). Placebo or 20K-hGH was administered sc to normal men (20–31 yr of age, n = 6–8 per group) at 2100 h. Serum 20K- and 22K-hGH levels were monitored every 30 min for 24 h by specific enzyme-linked immunosorbent assays. Serum free fatty acid, insulin-like growth factor I, insulin, and glucose levels were measured for 24 h. In the placebo group, the secretion profiles of endogenous 20K- and 22K-hGH were pulsatile and similar to each other. The proportion of 20K- to 22K-hGH was fairly constant. In the 20K-hGH-treated groups, serum 20K-hGH levels increased in a dose-dependent manner over the dose range of 0.01–0.1 mg/kg. Maximum serum 20K-hGH levels were reached at 3–4 h and decreased with half-lives of 2–3 h. Marked suppression of endogenous 22K-hGH secretion was observed in a time-dependent manner. Serum free fatty acid and insulin-like growth factor I levels were significantly elevated (P < 0.01) at 4, 8, and 12 h and at 8, 12, and 24 h after 20K-hGH administration, respectively. Serum insulin and glucose levels did not change significantly within 24 h. These results suggested that: 1) regulation of 20K-hGH secretion is physiologically the same as that of 22K-hGH; 2) the pharmacokinetics after sc injection of 20K-hGH are comparable with those of 22K-hGH; 3) 20K-hGH regulates hGH secretion through "GH-induced negative feedback mechanisms"; and 4) administration of 20K-hGH is expected to exert GH actions (growth-promoting activity and lipolytic activity). Monitoring of serum 20K- and 22K-hGH levels may be useful in evaluating the effects of administered GH isoforms on their own release from the pituitary.

This article has been cited by other articles:

				H. Liu, D. M. Bravata, I. Olkin, A. Friedlander, V. Liu, B. Roberts, E. Bendavid, O. Saynina, S. R. Salpeter, A. M. Garber, et al. Systematic Review: The Effects of Growth Hormone on Athletic Performance Ann Intern Med, May 20, 2008; 148(10): 747 - 758. [Abstract] [Full Text] [PDF]

				M. Hayakawa, Y. Shimazaki, T. Tsushima, Y. Kato, K. Takano, K. Chihara, A. Shimatsu, and M. Irie Metabolic Effects of 20-Kilodalton Human Growth Hormone (20K-hGH) for Adults with Growth Hormone Deficiency: Results of an Exploratory Uncontrolled Multicenter Clinical Trial of 20K-hGH J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1562 - 1571. [Abstract] [Full Text] [PDF]

				K.-C. Leung, C. Howe, L. Y.-Y. Gui, G. Trout, J. D. Veldhuis, and K. K. Y. Ho Physiological and pharmacological regulation of 20-kDa growth hormone Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E836 - E843. [Abstract] [Full Text] [PDF]